Bioxyne / Breathe Life Sciences (BLS)

Bioxyne Limited (ASX:BXN) is an Australian life sciences and health products business. In June 2023  Bioxyne acquired BLS in an all shares transaction becoming the parent company of Breathe Life Sciences (“BLS”) and DR Watson®.  The Group, which is headquartered in Sydney and has offices in London, Manchester, Prague, Brisbane, and Nagoya,  manufactures and distributes novel pharmaceuticals and consumer health products globally. 

BLS’ focus is in the development and commercialisation of medical cannabis, psychedelics, and novel foods and consumer health products under our own brands and manufacturing for third party brands. 

BLS’ goal is to become the market leading Australian manufacturer of novel pharmaceuticals and medicine products derived from Cannabis, Psilocybe Cubensis, and MDMA.  

In Australia, BLS is licensed to manufacture MDMA and Psilocybin products for commercial supply to authorised prescribers and clinical trials in Australia and global export markets. BLS was the first Australian company to receive its GMP license to manufacture MDMA and Psilocybin, and as of July 2024, remains the only licensed manufacturer in the country. 

In the UK and Europe BLS is a market leader in the supply of CBD (Cannabidiol) and functional mushroom products to national retailers and Amazon. BLS manufactures private, white label, and its in house brands in its UK and EU facilities. 

In the USA Bioxyne is currently selling PCC® to Nu-Skin Enterprises (USA) as the active ingredient in ProBio PCC™, and PCC® is being used in a number of other products currently sold in Europe and North America.

The Bioxyne team has extensive skills and knowledge in developing and commercialising life sciences technologies, health products and medicines. The Bioxyne board and management, backed by a supportive shareholder base, is positioned to pursue new growth opportunities for our products in Australasia, Europe, Asia and the USA.

DR Watson®

The Dr Watson brand was established in 2019 when it launched  its range of CBD lifestyle and consumer health products in the UK and Japan. In 2022 Dr Watson launched its medical cannabis range in Australia, supplying wholesale to pharmacies and clinics around the country. The Dr Watson product catalogue extends across multiple dose forms from pastilles (gummies), vape, oral mucosal oils, flower, and suppositories. 

Probiotic PCC^®

Bioxyne’s proprietary and clinically tested probiotic is Lactobacillus fermentum VRI-003 (PCC®). PCC® is supported by several clinical trials which describe its ability to boost immune and gastrointestinal health. The probiotic development is supported by a manufacturing agreement with Chr. Hansen (Denmark) a global leader in the manufacturing of probiotics and other dietary supplement products for the food, health, pharmaceutical and agriculture industries.

Bioxyne’s probiotic sales are led by ProBio PCC™, a probiotic product containing PCC® sold globally exclusively by Nu-Skin Enterprises (USA) a successful worldwide multilevel marketing company who offers only quality solutions to their customers.

Bioxyne sells its own branded PCC®-containing products in Australia: Progastrim® for gut and immune health and proTract® for atopic dermatitis (eczema).

Bioxyne is actively pursuing new opportunities in the immune health sector that will enhance future value for its shareholders. These include further clinical studies to develop new products to expand product range and to support the marketing of current products.